Materials
Presentations
Welcome to the Forum
Mitchell Leus, Forum for Collaborative Research
Introductory Remarks: HBV Forum Chairs
Veronica Miller, Forum for Collaborative Research
Marion Peters, Northwestern University
Oliver Lenz, Janssen Pharmaceuticals
Session I: HBV Biomarkers: Technical Updates and Database Opportunities
HBV RNA Assay Technical Updates and Applications
Fabien Zoulim, INSERM - French National Institute of Health and Medical Research
HBcrAg Assay Technical Updates and Applications
Man-Fung Yuen, University of Hong Kong
Biomarkers Database Working Group
Mitchell Leus, Forum for Collaborative Research
Panel Discussion
Jerome Bouquet, GSK
John Fry, Fry Scientific Consulting
Rémi Kazma, Roche
Wen Zeng*, FDA, Center for Drug Evaluation and Research
Session II: Bringing HBV Clinical Research to Africa
HBV Forum Session at 2023 African Hepatitis Summit
Veronica Miller, Forum for Collaborative Research
Landscaping of HBV Clinical Research in Africa
Nicaise Ndembi*, Africa Centres for Disease Control and Prevention
Panel Discussion
Danjuma Adda, World Hepatitis Alliance
Yasmin Ibrahim, Hepatitis B Foundation
Nicaise Ndembi*, Africa Centres for Disease Control and Prevention
Session III: Challenges in HDV Diagnostic Development
FDA Perspective on Hepatitis D In Vitro Diagnostic Devices
Kathleen Whitaker*, FDA, Center for Devices and Radiological Health
Panel Discussion
Chari Cohen, Hepatitis B Foundation
Tonya Hayden, Centers for Disease Control and Prevention
Saleem Kamili, Centers for Disease Control and Prevention
Kathleen Whitaker*, FDA, Center for Devices and Radiological Health
Session IV: Challenges in HDV Therapeutic Development
HDV Therapeutic Development: Lessons Learned from Bulevirtide
Pietro Lampertico, University of Milan
Why may siRNAs induce Flares in HBV/HDV Co-Infection?
Heiner Wedemeyer, Hannover Medical School
Session V: Checkpoint Inhibitors in HBV Clinical Development
Overview Presentation
Sue Currie, Virion Therapeutics
Adam Gehring, Toronto Centre for Liver Disease
